- By FYH News Team
[ad_1]
. 2022 May 17;S0027-9684(22)00085-2.
doi: 10.1016/j.jnma.2022.05.004.
Online ahead of print.
Affiliations
Affiliations
- 1 Division of Nephrology, Vanderbilt University Medical Center, Vanderbilt Center for Kidney Disease, United States.
- 2 Hattiesburg Clinic, Hattiesburg, MS, United States.
- 3 David Geffen School of Medicine at University of California, 7-155 Factor Bldg. 10833 LeConte Blvd, Los Angeles, CA 90095, United States. Electronic address: sunicholas@mednet.ucla.edu.
Item in Clipboard
Ebele M Umeukeje et al.
J Natl Med Assoc.
.
Display options
Format
. 2022 May 17;S0027-9684(22)00085-2.
doi: 10.1016/j.jnma.2022.05.004.
Online ahead of print.
Affiliations
- 1 Division of Nephrology, Vanderbilt University Medical Center, Vanderbilt Center for Kidney Disease, United States.
- 2 Hattiesburg Clinic, Hattiesburg, MS, United States.
- 3 David Geffen School of Medicine at University of California, 7-155 Factor Bldg. 10833 LeConte Blvd, Los Angeles, CA 90095, United States. Electronic address: sunicholas@mednet.ucla.edu.
Item in Clipboard
Display options
Format
Abstract
Diabetes and hypertension are the most common causes of chronic kidney disease (CKD) in the general population as well as in the Black and African American population, who also suffer from high rates of CKD and CKD progression compared to the White population. Progression of CKD can lead to kidney failure, and patients with progressive kidney disease have a high risk of premature mortality, particularly from cardiovascular disease. Screening for early detection of CKD is important as it facilitates the initiation of medications that have been shown to delay the progression of diabetes-related as well as non-diabetes-related CKD, and reduce rates of death from both kidney and cardiovascular disease. The potential adverse effects from use of some of the newer reno- and cardio-protective glucose-lowering medications, such as the sodium glucose cotransporter-2 inhibitors, may be effectively avoided with detailed patient education and monitoring by the healthcare provider. It is important to note that lifestyle modification including regular exercise, diet, and smoking cessation are first-line in the management of diabetes and hypertension. When CKD occurs, co-management by providers using a comprehensive strategy may avert early complications and facilitate appropriate early referral for nephrology specialty care.
Keywords:
Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Chronic kidney disease; Diabetes; Hypertension; Sodium glucose co-transporter-2 inhibitors.
Copyright © 2022 National Medical Association. All rights reserved.
Cite
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Victor Mejia
- Subash Kafle
- Subash Kafle



















